



The Abortion Act 1967 - Approval of a Class of Places

This approval supersedes the approval of 27 December 2018. This approval expires on the day on which the temporary provisions of the Coronavirus Act 2020 expire, or the end of the period of 2 years beginning with the day on which it is made, whichever is earlier.

The Secretary of State makes the following approval in exercise of the powers conferred by section 1(3) and (3A)¹ of the Abortion Act 1967²:

Interpretation

1. In this approval –

“home” means, in the case of a pregnant woman, the place in England where a pregnant woman has her permanent address or usually resides or, in the case of a registered medical practitioner, the place in England where a registered medical practitioner has their permanent address or usually resides;

“approved place” means a hospital in England, as authorised under section 1(3) of the Abortion Act 1967, or a place in England approved under that section.

Approval of class of place

2. The home of a registered medical practitioner is approved as a class of place for treatment for the termination of pregnancy for the purposes only of prescribing the medicines known as Mifepristone and Misoprostol to be used in treatment carried out in the manner specified in paragraph 4.

3. The home of a pregnant woman who is undergoing treatment for the purposes of termination of her pregnancy is approved as a class of place where the treatment for termination of pregnancy may be carried out where that treatment is carried out in the manner specified in paragraph 4.

4. The treatment must be carried out in the following manner-

a) the pregnant woman has-

i) attended an approved place;


¹ Section 1(3A) was inserted by section 37(3) of the Human Fertilisation and Embryology Act 1990 (c. 37).

² 1967 c. 87.

ii) had a consultation with an approved place via video link, telephone conference or other electronic means, or

iii) had a consultation with a registered medical practitioner via video link, telephone conference or other electronic means; and

b) the pregnant woman is prescribed Mifepristone and Misoprostol to be taken for the purposes of the termination of her pregnancy and the gestation of the pregnancy has not exceeded nine weeks and six days at the time the Mifepristone is taken.

A handwritten signature in black ink, appearing to read 'M. Davies'. The signature is fluid and cursive, with a large loop at the end of the last name.

Mark Davies

Director, Population Health

30 March 2020